SavedAdd your journal

Journals / Türk Onkoloji Dergisi / 2021 / Cilt: 36 - Sayı: 4

Investigation of Methylation Status of Homeobox D3 (HOXD3) and Protocadherin 17 (PCDH17) in Patients with Prostate Cancer

Berna DEMİRCAN
Asıf YILDIRIM
Özgür EFİLOĞLU
Hatice İKİIŞIK
Burcu YÜCEL
Alper KAYA
Aslı KARAMAN
Ahsen Merve BAYRAK
Pages
489–496
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION Our results indicated that HOXD3 and PCDH17 promoter methylation levels are higher in patients with prostate cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE Prostate cancer is one of the most common cancers in male gender.
📊
Key Findings & Data:The aim of this study is to investigate promoter methylation status of HOX3D and PCDH17 genes in prostate cancer in Turkish population.
💡
Conclusion & Impact:CONCLUSION Our results indicated that HOXD3 and PCDH17 promoter methylation levels are higher in patients with prostate cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE Prostate cancer is one of the most common cancers in male gender. Despite recent advances in the diagnosis and the treatment methods, more reliable molecular biomarkers have been needed for the diagnosis and evaluation of response to treatments such as chemotherapy, anti-androgen therapy, and radiotherapy. The aim of this study is to investigate promoter methylation status of HOX3D and PCDH17 genes in prostate cancer in Turkish population. METHODS A total of 46 patients with prostate cancer were included in this study. Tissue samples obtained from 36 patients with benign prostate hyperplasia were used as controls. Methylation status of HOXD3 and PCDH17 genes was determined by quantitative Methylation-Specific PCR with commercially available primer sets. RESULTS Both HOXD3 and PCDH17 promoter methylation was determined significantly higher in patients with compare to controls (p=0.0198 and p=0.0386, respectively). A significant but weak correlation was found between methylation status and pre-operative PSA level for HOXD3 (Spearman’s rho=0.259, p=0.02) and PCDH17 gene (Spearman’s rho=0.324, p=0.006). CONCLUSION Our results indicated that HOXD3 and PCDH17 promoter methylation levels are higher in patients with prostate cancer. Further studies with large sample cohorts and clinicopathological data will enlighten presumptive role of HOXD3 and PCDH17 methylation status.

🔖

Cite This Article

DEMİRCAN, B., YILDIRIM, A., EFİLOĞLU, Ö., İKİIŞIK, H., YÜCEL, B., KAYA, A., KARAMAN, A., BAYRAK, A. M. (2022). Investigation of Methylation Status of Homeobox D3 (HOXD3) and Protocadherin 17 (PCDH17) in Patients with Prostate Cancer. Türk Onkoloji Dergisi, Cilt: 36 - Sayı: 4, 489–496. https://ajindex.com/articles/639080

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Rawla P. Epidemiology of prostate cancer. World J Oncol 2019;10(2):63–89
  2. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020;77(1):38–52
  3. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Harb Cold Spring Perspect Med 2018;8(12):a030361
  4. Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: A review. JAMA 2017;317(24):2532– 42
  5. Tikkinen KA, Dahm P, Lytvyn L, Heen AF, Vernooij RW, Siemieniuk RA, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: A clinical practice guideline. BMJ (Online) 2018;362:k3581
  6. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: Results from the prostate cancer prevention trial. J Natl Cancer Inst 2006;98(8):529–34
  7. Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med 2018;378(7):645–57
  8. D’Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, et al. Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000;55(4):572–7
  9. Nebbioso A, Tambaro FB, Dell’Aversana C, Altucci L. Cancer epigenetics: Moving forward. PLoS Genet 2018;14(6):e1007362. 10.Yegnasubramanian S, de Marzo AM, Nelson WG. Prostate cancer epigenetics: From basic mechanisms to clinical implications. Cold Spring Harb Perspect Med 2019;9(4):a030445. 11.Wu Y, Sarkissyan M, Vadgama JV. Epigenetics in breast and prostate cancer. Methods Mol Biol 2015;1238:425– 66. 12.Cooper CS, Foster CS. Concepts of epigenetics in prostate cancer development. 2009;100(2):240-5. 13.Schulz WA, Hatina J. Epigenetics of prostate cancer: Beyond DNA methylation. J Cell Mol Med. 2006;10(1):100–25. 14.Cillo C, Faiella A, Cantile M, Boncinelli E. Homeobox genes and cancer. Exp Cell Res 1999;248(1):1–9. 15.Vega-Benedetti AF, Loi E, Moi L, Blois S, Fadda A, Antonelli M, et al. Clustered protocadherins methylation alterations in cancer. Clin Epigenet 2019;11(1):100. 16.Strand SH, Orntoft TF, Sorensen KD. Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci 2014;15(9):16544–76. 17.Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, et al. Epigenetics in prostate cancer: Biologic and clinical relevance. Eur Urol. 2011;60(4):753– 66. 18.Su J, Huang YH, Cui X, Wang X, Z